Walter V. Klemp - Jun 20, 2022 Form 4/A - Amendment Insider Report for Moleculin Biotech, Inc. (MBRX)

Role
CEO and President, Director
Signature
/s/ Jonathan Foster by Power of Attorney
Stock symbol
MBRX
Transactions as of
Jun 20, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
7/15/2022, 08:03 PM
Date Of Original Report
Jun 22, 2022
Previous filing
Jun 21, 2022
Next filing
Jul 15, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBRX Stock option (right to buy) Award +225K +33.29% 901K Jun 20, 2022 Common stock 225K $1.49 Direct F1, F2
transaction MBRX Restricted Stock Units Award +225K +24.98% 1.13M Jun 20, 2022 Common stock 225K Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.
F2 Issued in connection with the reporting person's employment with the Company.
F3 Each restricted stock unit represents a contingent right to receive one shares of Company common stock.
F4 The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.

Remarks:

As previously reported on a Form 4 filed on June 22, 2022 by the reporting person, the reporting person reported acquiring stock options to purchase 360,000 shares of common stock and 362,000 restricted stock units. However, the Company subsequently determined that stock options to purchase 135,000 shares of common stock and 137,000 restricted stock units granted under the Company's 2015 Stock Plan were not validly granted pursuant to the plan because they exceeded the limit on the number of stock options and restricted stock units that may be granted to any individual participant in one calendar year. Accordingly, the attempted grant of these excess stock options and restricted stock units was ineffective, and were not granted to the reporting person. The reporting person is filing this amendment to report the correct amount of stock options and restricted stock units acquired. The amounts set forth in column 9 are as of the date of the original filing and do not reflect any transactions since such date.